These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25145430)

  • 81. New pharmacoeconomic option in uremic anemia management.
    Savica V; Mantovani L; Santoro D; Ricciardi B; Bellinghieri G
    Clin Nephrol; 2007 Mar; 67(3):200. PubMed ID: 17390747
    [No Abstract]   [Full Text] [Related]  

  • 82. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
    Aapro M; Krendyukov A; Schiestl M; Gascón P
    BioDrugs; 2018 Apr; 32(2):129-135. PubMed ID: 29417431
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey.
    Cortinovis D; Beretta G; Piazza E; Luchena G; Aglione S; Bertolini A; Buzzoni R; Cabiddu M; Carnaghi C; Danova M; Farina G; Ferrari V; Frascaroli M; Reni M; Tansini G;
    Tumori; 2013; 99(1):45-50. PubMed ID: 23548999
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.
    Bohlius J; Bohlke K; Castelli R; Djulbegovic B; Lustberg MB; Martino M; Mountzios G; Peswani N; Porter L; Tanaka TN; Trifirò G; Yang H; Lazo-Langner A
    Blood Adv; 2019 Apr; 3(8):1197-1210. PubMed ID: 30971397
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Healthcare resource utilization for anemia management: current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A.
    Saueressig U; Kwan JT; De Cock E; Sapède C
    Blood Purif; 2008; 26(6):537-46. PubMed ID: 18997465
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
    Serna-Gallegos TR; La-Fargue CJ; Tewari KS
    Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Clinical and economic impact of epoetins in cancer care.
    Marchetti M; Barosi G
    Pharmacoeconomics; 2004; 22(16):1029-45. PubMed ID: 15524492
    [TBL] [Abstract][Full Text] [Related]  

  • 88. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
    Thill M
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.
    Bennett CL; Nagai S; Bennett AC; Hoque S; Nabhan C; Schoen MW; Hrushesky WJ; Luminari S; Ray P; Yarnold PR; Witherspoon B; Riente J; Bobolts L; Brusk J; Tombleson R; Knopf K; Fishman M; Yang YT; Carson KR; Djulbegovic B; Restaino J; Armitage JO; Sartor OA
    Oncologist; 2021 Aug; 26(8):e1418-e1426. PubMed ID: 33586299
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Treatment of anemia in Patient Blood Management from an economic perspective].
    Bisbe Vives E
    Rev Esp Anestesiol Reanim; 2015 Jun; 62 Suppl 1():80-5. PubMed ID: 26320350
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
    Goldsmith D; Dellanna F; Schiestl M; Krendyukov A; Combe C
    Clin Drug Investig; 2018 Jun; 38(6):481-490. PubMed ID: 29500617
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Biosimilar medicines used for cancer therapy in Europe: a review.
    Santos SB; Sousa Lobo JM; Silva AC
    Drug Discov Today; 2019 Jan; 24(1):293-299. PubMed ID: 30244082
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The approval process for biosimilar erythropoiesis-stimulating agents.
    Wish JB
    Clin J Am Soc Nephrol; 2014 Sep; 9(9):1645-51. PubMed ID: 24970875
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The ESA scenario gets complex: from biosimilar epoetins to activin traps.
    Jelkmann W
    Nephrol Dial Transplant; 2015 Apr; 30(4):553-9. PubMed ID: 24748667
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis.
    Aapro M; Moebus V; Nitz U; O'Shaughnessy J; Pronzato P; Untch M; Tomita D; Bohac C; Leyland-Jones B
    Ann Oncol; 2015 Apr; 26(4):688-695. PubMed ID: 25542926
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Potential cost savings associated with dose rounding antineoplastic monoclonal agents.
    Francis SM; Heyliger A; Miyares MA; Viera M
    J Oncol Pharm Pract; 2015 Aug; 21(4):280-4. PubMed ID: 24821690
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Comparative cost savings of biosimilar and dose rounding utilization in oncology care.
    Abdelmeseh V; Brown BR; Huynh JP; Zullo AR
    J Oncol Pharm Pract; 2023 Sep; 29(6):1437-1442. PubMed ID: 36259235
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Management of chemotherapy-induced anemia in lung cancer].
    Tiotiu A; Clément-Duchêne C; Martinet Y
    Rev Mal Respir; 2015 Oct; 32(8):809-21. PubMed ID: 26051503
    [TBL] [Abstract][Full Text] [Related]  

  • 99. What do oncologists need to know about biosimilar products?
    Leung LK; Mok K; Liu C; Chan SL
    Chin J Cancer; 2016 Oct; 35(1):91. PubMed ID: 27733189
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.
    Adams JR; Elting LS; Lyman GH; George JN; Lembersky BC; Armitage JO; Demetri GD; Bennett CL
    Am J Med; 2004 Jan; 116(1):28-34. PubMed ID: 14706663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.